Bottom line
In December 2024, the FDA approved Zepbound (tirzepatide) for moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity — the first time any drug has received an OSA indication. It's not a CPAP replacement for most patients, but it is a genuine alternative or adjunct.
In the SURMOUNT-OSA trials, patients on tirzepatide 10–15 mg had a mean reduction of 25–30 apnea-hypopnea events per hour over 52 weeks, compared to 5 on placebo. About 40–50% of treated patients achieved clinically meaningful resolution (AHI <5 or reduction of ≥50%).
What OSA is and why weight matters so much
Obstructive sleep apnea is characterized by repeated partial or complete airway collapse during sleep, measured by the apnea-hypopnea index (AHI — events per hour). Severity:
- Mild: AHI 5–15
- Moderate: AHI 15–30
- Severe: AHI ≥30
OSA affects an estimated 30 million U.S. adults and is severely underdiagnosed. Consequences include cardiovascular disease, hypertension, atrial fibrillation, stroke, daytime sleepiness, accidents, and mortality.
Obesity is the single strongest modifiable risk factor. Fat deposition around the upper airway (tongue base, soft palate, pharyngeal walls) narrows the airway; fat around the chest and abdomen reduces lung volumes and changes upper airway dynamics. Historically, meaningful weight loss was the only "cure" available, but it was rarely achieved with diet/exercise alone.
The SURMOUNT-OSA evidence
Two parallel trials enrolled 469 adults with moderate-to-severe OSA and obesity:
SURMOUNT-OSA-1 (not on CPAP at baseline): tirzepatide reduced AHI by a mean of 25 events/hour versus 5 on placebo. About 42% achieved AHI <5 (clinically defined resolution) or ≥50% reduction.
SURMOUNT-OSA-2 (on CPAP at baseline): tirzepatide reduced AHI by a mean of 29 events/hour versus 6 on placebo. About 50% achieved AHI <5 or ≥50% reduction.
Both trials saw mean body weight reductions of 17–19% on tirzepatide. Importantly, the AHI benefit was larger in both trials than would be predicted by weight loss alone — suggesting tirzepatide may have additional effects on airway dynamics or inflammation.
Is Zepbound going to replace your CPAP?
For most patients, no — at least not immediately. CPAP remains the first-line treatment for moderate-to-severe OSA with higher and faster efficacy. But Zepbound creates real options:
- Patients who refuse or can't tolerate CPAP (estimated 30–50% of
diagnosed OSA patients) now have a proven alternative.
- Patients on CPAP who hate it may be able to transition off after
achieving sufficient weight loss (typically 15%+).
- Patients with mild OSA plus obesity can often achieve resolution
on Zepbound alone.
A typical prescriber playbook in 2026: start Zepbound, maintain CPAP through weight loss, repeat sleep study at 6–12 months, consider CPAP reduction or discontinuation if AHI has normalized.
Why not Wegovy or Ozempic?
Only Zepbound has the FDA approval for OSA. Semaglutide (Wegovy, Ozempic) likely produces similar benefits proportional to its weight loss effect, but Novo Nordisk has not run the analogous trial yet.
For off-label use, Wegovy is a reasonable alternative for patients whose insurance covers it but not Zepbound.
Coverage: the biggest change in years
The Zepbound OSA approval has materially expanded insurance coverage. OSA is a covered medical diagnosis on essentially every commercial plan and Medicare — unlike "obesity," which Medicare Part D can't cover.
Medicare Part D has begun covering Zepbound for OSA in patients with documented moderate-to-severe OSA and qualifying BMI as of 2025. This is the first time Medicare has covered a GLP-1 for weight-related indications beyond the Wegovy/CVD carve-out.
Commercial plans have rapidly expanded OSA coverage for Zepbound through 2025 — often requiring a documented sleep study (home sleep apnea test or in-lab polysomnography) and AHI ≥15.
If you have OSA and have struggled to get GLP-1 coverage through the obesity pathway, the OSA pathway may succeed. Ask your prescriber whether your sleep study supports the diagnosis.
What to discuss with your sleep physician
- Your current AHI, oxygen desaturation index, and CPAP tolerance.
- Whether a repeat sleep study at 6–12 months post-weight-loss makes
sense.
- Whether CPAP pressures should be reduced as you lose weight (some
patients develop aerophagia on pressures set for a heavier body).
- Comorbidities that modify risk (A-fib, treated hypertension, prior
stroke).
Next steps
If you have OSA and obesity, the Zepbound drug page covers the full efficacy, cost, and dosing picture. The Sherpa Matcher will help you find telehealth programs that handle OSA-indication prescribing.